Melanoma is considered one of the most aggressive skin cancers. It spreads and
metastasizes quickly and is intrinsically resistant to most conventional chemotherapeutics …

Antibody drug conjugates (ADCs) are promising cancer therapeutics with minimal toxicity as
compared to small cytotoxic molecules alone and have shown the evidence to overcome …

A bispecific antibody (BsAb) targeting the epidermal growth factor receptor (EGFR) and
mesenchymal–epithelial transition factor (MET) pathways represents a novel approach to …

With the development of molecular cloning technology and the deep understanding of
antibody engineering, there are diverse bispecific antibody formats from which to choose to …

Bispecific antibodies (bsAbs) and antibody-drug conjugates (ADCs) have already
demonstrated benefits for the treatment of cancer in several clinical studies, showing …

Currently, four antibody-drug conjugates (ADCs) are approved by the Food and Drug
Administration or the European Medicine Agency to treat cancer patients. More than 60 …

Purpose The phase I study characterized the safety, pharmacokinetics, anti-tumor activity,
and recommended phase II dose/schedule of LY3164530 in patients with advanced or …

Bispecific antibodies (BsAbs) are antibodies with two different paratopes. In the past decade,
advances in protein engineering have enabled the development of more than 100 formats of …

Dual-targeted imaging agents have shown improved targeting efficiencies in comparison to
single-targeted entities. The purpose of this study was to quantitatively assess the tumor …

MET, the product of the c-MET proto-oncogene, and its ligand hepatocyte growth
factor/scatter factor (HGF/SF) control survival, proliferation and migration during …